Burden of basal cell carcinoma in USA

Future Oncology

Volumn 11, Issue 22, 2015, Pages 2967-2974

  Wu, Xinyuan ^a   Elkin, Elena E ^a   Marghoob, Ashfaq A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

basal cell carcinoma; burden; cost; cost analysis; cost effectiveness; economics; epidemiology; healthcare; incidence nonmelanoma; medicare; morbidity; population; procedures; registries; skin cancer; skin neoplasms; treatment modality; treatment pattern; trends; USA

Indexed keywords

ARTICLE; BASAL CELL CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HUMAN; METASTASIS; MORBIDITY; PRIORITY JOURNAL; UNITED STATES; CARCINOMA, BASAL CELL; COST BENEFIT ANALYSIS; INCIDENCE; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INCIDENCE; SKIN NEOPLASMS; UNITED STATES;

EID: 84946839619     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.180     Document Type: Article

References (35)

1. Mudigonda T, Pearce DJ, Yentzer BA, Williford P, Feldman SR. The economic impact of non-melanoma skin cancer: a review. J. Natl Compr. Cancer Netw. 8(8), 888-896 (2010).
2. Asgari MM, Bertenthal D, Sen S, Sahay A, Chren MM. Patient satisfaction after treatment of nonmelanoma skin cancer. Dermatol. Surg. 35(7), 1041-1049 (2009).
3. Rogers HW, Weinstock MA, Harris AR et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol. 146(3), 283-287 (2010).
4. Wilson LS, Pregenzer M, Basu R et al. Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting. Dermatol. Surg. 38(4), 570-584 (2012).
5. Wu S, Han J, Li WQ, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in US women and men. Am. J. Epidemiol. 178(6), 890-897 (2013).
6. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 166(5), 1069-1080 (2012).
7. Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 329(7468), 705 (2004).
8. Bolognia JL, Jorizzo JL, Rapini RP. Bolognia: Dermatology. Mosby-Elsevier, St Louis, MO, USA, 1784-1795 (2008).
9. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 327(7418), 794-798 (2003).
10. Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 117(2), e79-e82 (2013).
11. Cakir BO, Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast. Surg. Clin. North Am. 20(4), 419-422 (2012).
12. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol. Biomarkers Prev. 19(7), 1686-1695 (2010).
13. Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J. Am. Acad. Dermatol. 61(1), 96-103 (2009).
14. Kyle JW, Hammitt JK, Lim HW et al. Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children. Pediatrics 121(5), e1074-e1084 (2008).
15. Chen JG, Fleischer AB Jr. , Smith ED et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol. Surg. 27(12), 1035-1038 (2001).
16. Bureau of Labor Statistics: consumer price index-medical care. www. bls. gov/cpi/data. htm
17. Chen GJ, Yelverton CB, Polisetty SS et al. Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol. Surg. 32(10), 1266-1271 (2006).
18. Joseph AK, Mark TL, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol. Surg. 27(11), 955-959 (2001).
19. Manternach T, Housman TS, Williford PM et al. Surgical treatment of nonmelanoma skin cancer in the Medicare population. Dermatol. Surg. 29(12), 1167-1169; discussion 1169 (2003).
20. John Chen G, Yelverton CB, Polisetty SS et al. Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol. Surg. 32(10), 1266-1271 (2006).
21. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch. Dermatol. 145(12), 1431-1438 (2009).
22. Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol. Surg. 33(4), 433-440 (2007).
23. Roozeboom MH, Arits AHHM, Nelemans PJ, Kelleners-Smeets NWJ. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br. J. Dermatol. 167(4), 733-756 (2012).
24. Stern RS. Cost effectiveness of Mohs micrographic surgery. J. Invest. Dermatol. 133(5), 1129-1131 (2013).
25. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int. J. Dermatol. 45(5), 489-498 (2006).
26. Essers BaB, Dirksen CD, Nieman FHM et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch. Dermatol. 142(2), 187-194 (2006).
27. Seidler AM, Bramlette TB, Washington CV, Szeto H, Chen SC. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol. Surg. 35(11), 1776-1787 (2009).
28. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int. J. Cancer 121(9), 2105-2108 (2007).
29. Congressional Budget Office: Medicare. www. cbo. gov/topics/health-care/medicare
30. Meadows AT, Friedman DL, Neglia JP et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J. Clin. Oncol. 27(14), 2356-2362 (2009).
31. Perkins JL, Liu Y, Mitby PA et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 23(16), 3733-3741 (2005).
32. Giacomel J, Zalaudek I. Dermoscopy of superficial basal cell carcinoma. Dermatol. Surg. 31(12), 1710-1713 (2005).
33. Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J. Drugs Dermatol. 8(10), 914-922 (2009).
34. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 29(10), 863-874 (2011).
35. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N. Engl. J. Med. 353(21), 2262-2269 (2005).